Merck taps five Indian drugmakers to expand Covid-19 drug production

Merck taps five Indian drugmakers to expand Covid-19 drug production



Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.


The partnership will give the companies license to supply Merck’s molnupiravir to India and more than 100 low- and middle-income countries following approvals or emergency authorization by local regulatory agencies, Merck said.



Merck said the move is to help address the raging new wave of COVID-19 in India, which has reported more than 300,000 new COVID-19 cases per day over the past six days.


Drugmaker Gilead Sciences Inc on Monday said it will give India at least 450,000 vials of its antiviral drug, remdesivir, and help boost production in the country.


Merck’s non-exclusive production pacts for molnupiravir are with companies including Dr.Reddy’s Laboratories Ltd and privately held companies Emcure Pharmaceuticals Ltd and Hetero Labs Ltd.


Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics for the treatment of non-hospitalized COVID-19 patients.


Merck has decided to focus on its drugs for COVID-19 after two vaccines failed to generate desired immune responses, prompting it to abandon the program in January.


(Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M. And Shinjini Ganguli)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *